» Articles » PMID: 34285405

The Aetiology and Molecular Landscape of Insulin Resistance

Overview
Date 2021 Jul 21
PMID 34285405
Citations 190
Authors
Affiliations
Soon will be listed here.
Abstract

Insulin resistance, defined as a defect in insulin-mediated control of glucose metabolism in tissues - prominently in muscle, fat and liver - is one of the earliest manifestations of a constellation of human diseases that includes type 2 diabetes and cardiovascular disease. These diseases are typically associated with intertwined metabolic abnormalities, including obesity, hyperinsulinaemia, hyperglycaemia and hyperlipidaemia. Insulin resistance is caused by a combination of genetic and environmental factors. Recent genetic and biochemical studies suggest a key role for adipose tissue in the development of insulin resistance, potentially by releasing lipids and other circulating factors that promote insulin resistance in other organs. These extracellular factors perturb the intracellular concentration of a range of intermediates, including ceramide and other lipids, leading to defects in responsiveness of cells to insulin. Such intermediates may cause insulin resistance by inhibiting one or more of the proximal components in the signalling cascade downstream of insulin (insulin receptor, insulin receptor substrate (IRS) proteins or AKT). However, there is now evidence to support the view that insulin resistance is a heterogeneous disorder that may variably arise in a range of metabolic tissues and that the mechanism for this effect likely involves a unified insulin resistance pathway that affects a distal step in the insulin action pathway that is more closely linked to the terminal biological response. Identifying these targets is of major importance, as it will reveal potential new targets for treatments of diseases associated with insulin resistance.

Citing Articles

Skeletal muscle atrophy and dysfunction in obesity and type-2 diabetes mellitus: Myocellular mechanisms involved.

Castillo I, Argiles J, Rueda R, Ramirez M, Pedrosa J Rev Endocr Metab Disord. 2025; .

PMID: 40064750 DOI: 10.1007/s11154-025-09954-9.


Joint assessment of abdominal obesity and non-traditional lipid parameters for primary prevention of cardiometabolic multimorbidity: insights from the China health and retirement longitudinal study 2011-2018.

Lai H, Tu Y, Liao C, Zhang S, He L, Li J Cardiovasc Diabetol. 2025; 24(1):109.

PMID: 40057762 PMC: 11890515. DOI: 10.1186/s12933-025-02667-y.


An atypical atherogenic chemokine that promotes advanced atherosclerosis and hepatic lipogenesis.

El Bounkari O, Zan C, Yang B, Ebert S, Wagner J, Bugar E Nat Commun. 2025; 16(1):2297.

PMID: 40055309 PMC: 11889166. DOI: 10.1038/s41467-025-57540-z.


Cardiovascular risk prediction in hemodialysis patients using the triglyceride-glucose index: a multicenter prospective cohort study.

Lee Y, Kang S, Kim D, Kim J, Jeong K, Kim Y Clin Kidney J. 2025; 18(3):sfaf016.

PMID: 40052161 PMC: 11883225. DOI: 10.1093/ckj/sfaf016.


Association between the triglyceride glucose-body mass index and mortality risk in cardiovascular disease populations: a longitudinal cohort study.

Chen B, Wang H, Xu S, Zeng D, Liu S, Pan X BMC Public Health. 2025; 25(1):822.

PMID: 40022003 PMC: 11871752. DOI: 10.1186/s12889-025-22018-6.


References
1.
Himsworth H . Diabetes mellitus: its differentiation into insulin-sensitive and insulin-insensitive types. 1936. Int J Epidemiol. 2014; 42(6):1594-8. DOI: 10.1093/ije/dyt203. View

2.
Petersen M, Shulman G . Mechanisms of Insulin Action and Insulin Resistance. Physiol Rev. 2018; 98(4):2133-2223. PMC: 6170977. DOI: 10.1152/physrev.00063.2017. View

3.
Philipson L . Harnessing heterogeneity in type 2 diabetes mellitus. Nat Rev Endocrinol. 2019; 16(2):79-80. PMC: 8035709. DOI: 10.1038/s41574-019-0308-1. View

4.
Ahlqvist E, Storm P, Karajamaki A, Martinell M, Dorkhan M, Carlsson A . Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018; 6(5):361-369. DOI: 10.1016/S2213-8587(18)30051-2. View

5.
Erion K, Corkey B . Hyperinsulinemia: a Cause of Obesity?. Curr Obes Rep. 2017; 6(2):178-186. PMC: 5487935. DOI: 10.1007/s13679-017-0261-z. View